PTC Therapeutics, Inc.
PTCTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States. Valued at $5.06B, PTCT is a mid-cap name in its sector. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Market Cap
$5.06B
Beta
0.49
P/E (TTM)
—
P/E (Fwd)
25.57
EPS (TTM)
$-0.65
EPS (Fwd)
$2.37
ROE
—
ROA
2.5%
Cash
$2.23B
Total Debt
$3.02B
Free CF
-$286.8M
52W Change
-9.7%
Annual Financials
Cash vs Debt
Where PTCT stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, PTCT finished 16.83% below its 150-day moving average ($71.23) and 17.04% below its 200-day moving average ($71.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PTCT overbought or oversold?
At the October 19, 2026 close, PTCT's RSI(14) was 26.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, PTCT has $2.23B in cash with $3.02B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$286.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROA of 2.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $698.8M (2022) to $1.73B (2025), reflecting a 148% increase over the period.
With a beta below 0.7, PTC Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence PTC Therapeutics, Inc.'s trajectory.